Read by QxMD icon Read

meningioma vegfr 1

Tareq A Juratli, Kathrin D Geiger, Patrick Weigel, Maja von der Hagen, Dirk Daubner, Thomas Pinzer, Gabriele Hahn, Gabriele Schackert, Matthias Kirsch
BACKGROUND: Only a few cases have been previously published about clear cell meningiomas in children, the majority of them in the location of the spine. We describe an unusual case of clear cell meningioma occurring at the petro-clival region in a 5-year-old child. We further seek to determine the impact of several growth factors as well as the AKT1 mutation on the tumor growth pattern. CASE PRESENTATION: A five-year-old girl was presented with a one-week history of cephalgia, ataxia, and left sided torticollis...
November 2015: Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic, Andrew Norden, Jan Drappatz, Eudocia Quant Lee, Benjamin Purow, Scott R Plotkin, Tracy Batchelor, Lauren E Abrey, Antonio Omuro
BACKGROUND: No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor, abundant in meningiomas. METHODS: This was a prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with surgery and radiation-refractory recurrent World Health Organization (WHO) grades II-III meningioma...
January 2015: Neuro-oncology
Damoun Nassehi
Meningiomas are the second-most common intracranial tumours in adults. They are derived from the arachnoid cells, and although approximately 90% of meningiomas are benign, more than half of all meningiomas develop peritumoral brain oedema (PTBE), which increases morbidity. The PTBE can be treated with steroid therapy, but this treatment is not specific, is not always effective, and involves long-term side-effects. Meningiomas are treated with radiation therapy, stereotactic radio-surgery or surgical resection...
April 2013: Danish Medical Journal
Damoun Nassehi, Lars P Sørensen, Henrik Dyrbye, Carsten Thomsen, Marianne Juhler, Henning Laursen, Helle Broholm
The aim of this work was to study the vascular endothelial growth factor A (VEGF-A) pathway and peritumoral brain edema (PTBE) through comparison of non-angiomatous and angiomatous meningiomas. Meningiomas are common intracranial tumors, which often have PTBE. VEGF-A is an integral part of PTBE formation and angiogenesis, and the capillary-rich angiomatous meningiomas are known for their PTBE. The VEGF-A receptor VEGFR-2 is responsible for the angiogenic effect of VEGF-A on endothelial cells, which is enhanced by the co-receptor neuropilin-1...
November 2013: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley
Atypical and anaplastic (WHO Grades II and III) meningiomas are aggressive tumors, and patients often progress despite surgery and radiation. There is no known effective chemotherapeutic option for these patients. Meningiomas have a high expression of vascular endothelial growth factor receptor (VEGFR). We sought to retrospectively study the activity of bevacizumab, which is an anti-angiogenic agent targeting the VEGF pathway in these tumors. This is a retrospective review of WHO Grade II and III meningiomas treated at four institutions, selecting only those patients who received bevacizumab...
August 2012: Journal of Neuro-oncology
Matthias Preusser, Marco Hassler, Peter Birner, Margaretha Rudas, Till Acker, Karl H Plate, Georg Widhalm, Engelbert Knosp, Helene Breitschopf, Johannes Berger, Christine Marosi
AIM: We studied expression of molecules of the vascular endothelial growth factor (VEGF) pathway and its relation to vascularization, cell proliferation and patient outcome in recurring non-anaplastic meningioma. We studied 29 tumor specimens of 8 patients with recurring meningiomas and of 8 age- and gender-matched control patients with non-recurring meningiomas (including meningothelial, transitional, fibroblastic and atypical subtypes) using immunohistochemistry and in-situ hybridization...
September 2012: Clinical Neuropathology
Peng Gao, Yongmei Chen, Michael T Lawton, Nicholas M Barbaro, Guo-Yuan Yang, Hua Su, Feng Ling, William L Young
BACKGROUND: Brain and spinal cord arteriovenous malformations (AVMs) are characterized by aberrant angiogenesis and vascular remodeling. Endothelial progenitor cells (EPCs) can be recruited by stromal cell-derived factor-1 (SDF-1), and participate in vascular remodeling in both physiological and pathological settings. OBJECTIVE: To investigate whether there are increased EPC levels in the brain and spinal cord AVM nidus. METHODS: Microsurgical specimens without endovascular embolization and radiosurgery from the brain (n = 12) and spinal cord (n = 5) AVMs were examined...
October 2010: Neurosurgery
Toshio Uesaka, Tadahisa Shono, Satoshi O Suzuki, Akira Nakamizo, Hiroaki Niiro, Masahiro Mizoguchi, Toru Iwaki, Tomio Sasaki
Vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis in various brain tumors. In this study, we determined the expression levels of VEGF, and vascular endothelial growth factor receptor (VEGFR)-1 and -2 mRNA in 46 intracranial schwannomas by quantitative real-time PCR, and correlated these with various clinical factors or other molecular markers. We found that these tumors expressed significant amounts of VEGF mRNA in comparison with other brain tumors, including malignant gliomas and meningiomas...
July 2007: Journal of Neuro-oncology
Hongguang Huang, Janka Held-Feindt, Ralf Buhl, Hubertus M Mehdorn, Rolf Mentlein
INTRODUCTION: Vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 and -2 are considered to play a major in tumor angiogenesis, which is a prerequisite for growth of solid tumors. Glioblastoma multiforme is a prominent example of VEGF-induced tumor vascularization; however, little is known about VEGF and in particular VEGFR expression in other types of brain tumors. METHODS: VEGFR mRNA was quantified by real time RT-PCR in 12 different types of brain tumors and compared to VEGF protein content measured by ELISA...
June 2005: Neurological Research
S Donnini, M R Machein, K H Plate, H A Weich
It has previously been suggested that in human brain tumours, endothelial cell proliferation during angiogenesis is regulated by a paracrine mechanism involving vascular endothelial growth factor (VEGF) and its receptors (VEGF receptor 1 and VEGF receptor 2). The mechanism of growth factor up-regulation is based on hypoxic activation of mRNA expression and mRNA stabilization and genetic events, leading to an increase of growth factor gene expression. The role of the other newly discovered VEGF family members with a high specificity for endothelial cells in the pathogenesis of glial neoplasms is unknown...
September 1999: Journal of Pathology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"